Both in theory and in practice insight is limited about how firms in dynamic environments could organize to manage concurrently the strategic processes of exploring new knowledge and exploiting existing knowledge. To contribute to this issue, a conceptual framework is developed which considers the ability to exchange knowledge across organization-units within a firm as a prerequisite to achieve...

شاخص سطح برگ استخراج‌شده (LAI) از تصاویر سنجش دور پارامتر مهمی، به‌منظور مدل‌سازی مکانی تولید پوشش گیاهی، محسوب می‌شود. معمولاً شاخص‌های گیاهی که با بازتاب طول موج‌های قرمز و مادون نزدیک محاسبه می‌شوند، در برآورد LAI استفاده روش‌های آماری، به‌کار می‌روند اما بسیاری این شاخص‌ها مقادیر متفاوت به اشباع می‌رسند. برای رفع محدودیت، محدودة لبة شده است؛ بنابراین، باید قابلیت داده‌های دور، ذرت علوفه‌ای، ...

From Jefferson Medical College, Hockessin, Del. Supported by funding from Wyeth Pharmaceuticals, Philadelphia, Pa. Dr. Lieberman serves as a consultant to Abbott, Cephalon, Bristol-Myers, Forest, Janssen, Lilly, Novartis, Organon, Novo Nordisk, Pfizer, Ortho-McNeil, and Sanofi-Synthelabo. Corresponding author and reprints: Joseph A. Lieberman III, M.D., M.P.H., Jefferson Medical College, 2 Asto...

Meningococcal ABCWY Vaccine Formulations in Adolescents and Young Adults Stan L. Block, MD; Leszek Szenborn, MD; Wendy Daly, MD; Teresa Jackowska, MD; Vas Narasimhan, MD; Diego D’Agostino, MSc; Linda Han, MD; Peter M Dull, MD; Igor Smolenov, MD; Kentucky Pediatric and Adult Research Center, Bardstown, KY; Clinic of Pediatrics and Infectious Diseases, Wroclaw, Poland; Bluegrass Clinical Research...

INTRODUCTION Tegaserod maleate (ZelnormTM, Novartis) is a unique pharmacological agent for the treatment of patients with irritable bowel syndrome (IBS) with constipation (IBS-C). Unlike traditional IBS therapies, which target only single IBS symptoms, tegaserod has provided global relief of the multiple symptoms of IBS, including abdominal pain and discomfort, bloating, and constipation.1–4 It...

Nearly 20 years later, Druker the physician has helped a better way materialize in the form of STI571, a drug that selectively targets chronic myelogenous leukemia cells without any of the traditional chemotherapy side effects. The darling of two recent scientific conferences, STI571, which is owned by Novartis Pharmaceuticals Corp., East Hanover, N.J., passed phase I clinical testing with prom...